Results 41 to 50 of about 224,807 (304)
Summary: Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor
Justin H. Hwang +31 more
doaj +1 more source
Direct action through the Sertoli cells is essential for androgen stimulation of spermatogenesis [PDF]
Androgens act to stimulate spermatogenesis through androgen receptors (AR) on the Sertoli cells and peritubular myoid cells (PTM). Specific ablation of the AR in either cell type will cause a severe disruption of spermatogenesis.
Abel, M.H. +4 more
core +1 more source
BackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Jianqing Wang +9 more
doaj +1 more source
Antagonists of growth hormone-releasing hormone (GHRH) could extend the duration of response of androgen sensitive prostate cancers to androgen deprivation.
Stangelberger, Anton +8 more
core +1 more source
Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer [PDF]
Non-steroidal anti-androgens have a major role in the treatment of non-localized prostate cancer. Interleukins are involved in the regulation of many cellular functions in prostate cancer and also modify cellular response to anti-androgens. A specific role of selected IL is presented in this review.
openaire +2 more sources
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease ...
Hadjer Dellal +8 more
doaj +1 more source
Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists [PDF]
Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists.
core
Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
The management of hormone-refractory prostate cancer represents a major challenge in the therapy of this tumor, and identification of novel androgen receptor antagonists is needed to render treatment more effective.
Anna Tesei +13 more
doaj +1 more source
Background: Prostate cancer is a disease that occurs in men aged more than 50 years. In Iraq, 8.89 men per 100,000 population suffer from prostate cancer, with the incidence being 14,016 cases and mortality being 6,367 cases.
Hany Akeel Al-Hussaniy +2 more
doaj +1 more source
Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy [PDF]
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant
core

